Vanessa Malier (L) and Rémi Droller, managing partners at Kurma Partners
March 8, 2022 10:38 AM ESTUpdated 03:29 PM
Financing

Kur­ma scores $175M in first clos­ing of biotech/healthtech fund — the VC's largest yet

Paul Schloesser

Associate Editor

French VC Kur­ma has been in­vest­ing in­to sev­er­al com­pa­nies re­cent­ly, such as AR­M­GO Phar­ma and Emer­gence Ther­a­peu­tics. With its new biotech and healthtech-fo­cused fund, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times